Aspira Pathlab & Diagnostics Ltd.

30.15 +0.09 ▲0.3%

19 April 2024, 04:01:00 PM
Volume: 1,744

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Industry Icon Hospital & Healthcare Services Compare with Industry peers
Website http://www.aspiradiagnostics.com
Market Cap 31.03 Cr.
Enterprise Value(EV) 30.65 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -2.36 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 66.57 Trailing Twelve Months Ending 2023-12
Book Value / Share 10.28 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.93 Calculated using Price: 30.15
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.03 Cr. 10,293,000 Shares
FaceValue 10
About Aspira Pathlab & Diagnostics Ltd.
The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.

Aspira Pathlab & Diagnostics Ltd. Delivery

Delivered Qty
Traded Qty

Aspira Pathlab & Diagnostics Ltd. Performance

1 Day
+0.30%
1 Week
-6.57%
1 Month
-6.42%
3 Month
-4.59%
6 Month
-19.60%
1 Year
-5.78%
2 Year
-57.23%
5 Year
-4.59%
10 Year

Aspira Pathlab & Diagnostics Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 1.1 0.76 -57.04 -178.61 -187.57 -94.32 22.8 42.26 -0.69
Return on Capital Employed (%) 3.95 1.78 -25.35 -38.38 -34.5 -26.3 21.52 41.63 2.4
Return on Assets (%) 1.05 0.54 -25.76 -40.76 -37.93 -29.11 10.58 29.82 -0.5

Aspira Pathlab & Diagnostics Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 4 4 6 0 5 4 8 13 13 11
Non Curr. Liab. 3 11 5 5 1 4 3 3
Curr. Liab. 0 3 6 2 4 5 2 2 2 2
Minority Int.
Equity & Liab. 4 6 15 13 15 14 12 18 17 16
Non Curr. Assets 1 11 11 13 11 8 11 11 11
Curr. Assets 4 6 4 2 2 3 4 7 6 5
Misc. Exp. not W/O
Total Assets 4 6 15 13 15 14 12 18 17 16

Aspira Pathlab & Diagnostics Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 1 4 8 8 15 20 14 13
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 1 5 8 9 15 20 15 13
Total Expenditure 0 0 -3 -8 -11 -10 -12 -13 -13 -14
PBIDT 0 0 -2 -4 -3 -2 4 6 2 -1
Interest 0 0 0 -1 -1 -1 -1 0 0 0
Depreciation 0 -1 -1 -2 -1 -2 -2 -2
Taxation 0 0 0
Exceptional Items
PAT 0 0 -3 -6 -5 -4 1 4 0 -2
Adjusted EPS 0 0 -5 -11 -6 -5 1 4 0 -2

Aspira Pathlab & Diagnostics Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 0 -1 -5 -3 -2 6 2 0
Cash Fr. Inv. 0 0 0 -10 -1 -2 0 0 -1 0
Cash Fr. Finan. 3 3 9 7 3 1 -2 -1 -1
Net Change 0 3 2 -3 1 -2 0 3 0 -1
Cash & Cash Eqvt 0 3 5 3 0 -2 -2 1 1 1

Aspira Pathlab & Diagnostics Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 36.25 36.25 36.19 34.55 19.48 19.47 19.37 18.90 18.90
Public 63.75 63.75 63.81 65.45 80.52 80.53 80.63 81.10 81.10
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Aspira Pathlab & Diagnostics Ltd. Announcements

Wed, 17 Apr 2024
Compliance Certificate As Per Regulation 7(3) Of The SEBI(LODR)Regulations 2015 For The Financial Year Ended March 31 2024.
Enclosed herewith Compliance Certificate pursuant to regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the Financial Year ended March 31 2024.
Wed, 10 Apr 2024
Compliance Certificate Under Regulation 40(9 & 10) Of The SEBI (LODR) Regulations 2015 For The Year Ended March 31 2024
Pursuant to regulation 40(9 & 10) of the SEBI (LODR)Regulations 2015 we enclose herewith certificate from Practicing Company Secretary for the period from April 01 2023 to March 31 2024.
Tue, 09 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyAspira Pathlab & Diagnostics Ltd
2CIN NO.L85100MH1973PLC289209
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Krupali Shah
Designation: Company Secretary
EmailId: krupali.shah@aspiradiagnostics.com
Name of the Chief Financial Officer: Balkrishna Talawadekar
Designation: Chief Financial Officer
EmailId: balkrishna.talawadekar@aspiradiagnostics.com

Date: 09/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Aspira Pathlab & Diagnostics Ltd. Technical Scans

Fri, 19 Apr 2024
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Aspira Pathlab & Diagnostics Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 365,310.75 1,525.00 +0.5%
Cipla Ltd. 108,622.88 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. 99,134.26 5,942.65 -0.3%
Divi's Laboratories Ltd. 97,408.39 3,673.85 -1.2%
Mankind Pharma Ltd. 93,565.44 2,362.00 -1.5%
Zydus Lifesciences Ltd. 92,794.90 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. 88,715.85 6,152.25 +1.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.02 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-12 29.29 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 18.96 5,942.65 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-12 70.43 3,673.85 -1.2%
Mankind Pharma Ltd. Consolidated 2023-12 54.18 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.20 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 112.40 6,152.25 +1.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.85 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-12 4.19 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.69 5,942.65 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-12 7.47 3,673.85 -1.2%
Mankind Pharma Ltd. Consolidated 2023-12 10.53 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.92 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.14 6,152.25 +1.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 0.02 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,942.65 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,673.85 -1.2%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,152.25 +1.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,942.65 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,673.85 -1.2%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,152.25 +1.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,942.65 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,673.85 -1.2%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,152.25 +1.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,942.65 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,673.85 -1.2%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,152.25 +1.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,942.65 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,673.85 -1.2%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,152.25 +1.4%

Aspira Pathlab & Diagnostics Ltd. FAQ's

What is Aspira Pathlab&Diagn share price?

Can I buy Aspira Pathlab&Diagn shares now?

What is the Market Cap of Aspira Pathlab&Diagn?

What are the key metrics to analyse Aspira Pathlab&Diagn?

What is the 52 Week High and Low of Aspira Pathlab&Diagn?

What is the trend of Aspira Pathlab&Diagn share price?